Dr. Anthony Schwartz is the Chief Executive Officer of Morphiex Biotherapeutics Corporation. The company is pursuing the clinical development of a novel immunotherapy to treat various forms of cancer. Anthony has over 15 years of experience in the biotechnology industry founding over 10 startups and serving in executive positions of several Health IT and biotechnology companies. In addition, Anthony is a Principle at BioVisors Consulting, a firm that advises biotechnology companies on corporate development, clinical trials and licensing opportunities. He has raised millions in non-diluted funding, supported the development of an FDA approved diagnostic and a moved pipeline of oncology and autoimmune therapeutics through IND. He worked with the National Institutes of Health/National Cancer Institute to advance Morphiex’s lead CD47 asset, MBT-001, into the clinic and is considered a Key Opinion Leader in the CD47 space. Dr. Schwartz has published multiple publications in prestigious journals and holds patents on a class of drugs attenuating the immune system for the treatment of cancer and diabetes. Anthony received his Ph.D. from Colorado State University in Biomedical Engineering with research focused on the immune system’s role in cancer, novel radiation therapies and stem cells.